development of new drugs
TRANSCRIPT
38
any part of the skin. The response was blocked bysubcutaneous procaine. The intradermal injection of0-02 ml. of heparinised plasma, derived from a sampleof the patient’s blood which had been kept at 38°C for90 minutes,
" produced a slight erythema comparable tothat produced by saline ", whereas the injection of
heparinised plasma, derived from the patient’s bloodwhen it had been kept at 4°C for 90 minutes and then
rewarmed, " produced significantly greater erythema ".This response was not found in normal subjects reinjectedwith their own plasma from chilled whole-blood samples.Chilled plasma freshly drawn from the patient (and, it isimplied, containing few platelets) did not result in
erythema when injected into his skin. No cryoglobulins,cold haemagglutinins, or cold hsemolysins were found;and no degranulation was seen when the basophil leuco-cytes were chilled in an ice bath for 15 minutes, indicatingthat the cutaneous response in this patient was distinctfrom the cold-urticaria reaction.2 4
Shelley and Caro suggest that cooling of the skin of theirpatient caused local vasoconstriction which then inducedaxon-reflex vasodilatation and sweating. They argue that,since intradermal serotonin will cause similar axon-reflexflares, liberation of this substance may well be the basisof the lesion. Circulating serotonin is normally boundto platelets; if the patient’s platelets were abnormallyunstable in the cold, their breakdown could releaseserotonin and so enable it to produce its unpleasanteffects. Unfortunately, Shelley and Caro were not ableto study the patient as fully as they wished, and for thepresent this interesting hypothesis lacks proof. They donot say whether the sweating-so striking a feature in theareas of skin exposed to cold-was reproduced by theintradermal injection of serotonin. A variety of serotoninantagonists failed to abolish the abnormal response whengiven orally, but their effect when given intradermallymight repay study. The crucial experiment, however,would be the measurement of free plasma-serotonin 5after platelet-rich plasma had been cooled to various
temperatures.
DEVELOPMENT OF NEW DRUGS
ONE of the vices of civilisation is to take too much for
granted. Because so many things are now made infactories rather than under our eyes, we underestimate the
ingenuity and toil that so often go into their making.A case in point is the modern drug; and the Practitioner
has done a service by devoting much of its January issueto articles explaining the almost fabulous effort requiredto produce the tablets, ampoules, capsules, elixirs, andsuspensions which are now so much a part of our dailylives. Dr. W. P. Kennedy, who opens the series, recallsan occasion on which a tablet of cortisone was exhibitedwith a label " This tablet cost$1,000,000 "-which,when one considers the facts, seems a very modestestimate. He quotes figures showing that in 1960 a
group of British pharmaceutical firms spent aboutt71 í million on the discovery and development of newand important drugs; and the other Practitioner articlesmake it clear that expenditure on such a scale is a necessityin view of the commercial hazards involved and the
complexity of the trials needed.In the medical profession, most of us pay too little
4. Shelley, W. B., Juhlin, L. Nature, Lond. 1961, 191, 1056.5. Robertson, J. I. S., Andrews, T. M. Lancet, 1961, i, 578.
attention to these trials until-as happens so rarely-something goes seriously wrong. Naturally, some of thearticles reflect the concern aroused everywhere last yearby the disaster with thalidomide, and Prof. GeorgeBrownlee refers to the possible introduction of a pro-bationary period of perhaps five years after a drug isreleased. On this he says:
" Four stages in the development of a new drug may betraced. They are the experimental animal tests, the clinicalinvestigation tests in man, the clinical trials, and the stage atwhich the drug is generally prescribed. It is evident that allactive drugs are toxic and are metabolized and their metabolicproducts also may be toxic. It is seen that toxicities may beobserved at all four stages and although those seen in animalsare likely always to be seen in man, those seen in man mayoften not be reproducible in animals. For these reasons it isunlikely that the predictable and the unpredictable toxicitiesof drugs will have been seen in man until a period of years haselapsed. Would it not be wise to look on those years as a
probationary period ?"
SURGERY OF RENAL-ARTERY ANEURYSM
ANEURYSM of the renal artery can no longer be con-sidered rare: at least 180 cases have been reported.! Inabout a third of these the sac was calcified and partlythrombosed, and the diagnosis could be made with somecertainty from the ring-shadow appearance on plainX-ray. But in the remainder the sac was not calcified, anda quarter of these presented acutely with rupture of theaneurysm and intra-abdominal haemorrhage. Even a pea-sized aneurysm can be responsible for such catastrophe,and (as in the similar and sometimes coincident conditionof splenic-artery aneurysm) the victim is quite often ayoung pregnant woman. The mortality for the wholereported series of ruptures was forbiddingly high at 75%.Other modes of presentation included are intermittentupper-abdominal pain, hsematuria, hypertension (particu-larly when the artery is stenosed proximal to the aneurysm),and renal atrophy. Ring opacity in the renal hilus canalso be due to calcified nodes or cysts, tuberculoma,calcified hxmatoma, or the calcified tortuous renal arteryitself; aortography may be necessary before these can bedistinguished. Aortography has also shown that, in mostrenal aneurysms, by the time the wall is calcified it is also-fortunately-strengthened by contained thrombus.This is commonly so in elderly patients, and no operationis then necessary; but should such a condition be
suspected in a pregnant woman, then exploratory opera-tion must be seriously contemplated.The surgeon may well wonder what to do when he finds
the aneurysm. Experience of 115 cases showed that
nephrectomy was the safest course 2: of 53 cases so treatedonly 3 were fatal, compared with 9 of 19 cases in whichsome conservative operation was attempted. In 1957Poutasse 3 reported a personal series of 12 cases of renal-artery aneurysm. These included 2 cases where, althoughthe sac was more than 2-5 cm. in diameter, it was dis-sected free from the side of the renal artery; the lateraldefect was then closed with a vascular suture. In each
’ case, subsequent intravenous pyelography displayednormal renal outline and function; and, in 1, aortographyshowed that the renal circulation was normal besides.
Operations of this type were tried, and met with success,1. Harrow, B. R., Sloane, J. S. J. Urol. 1959, 81, 35.2. Abeshouse, B. S. Urol. cutan. Rev. 1951, 55, 451.3. Poutasse, E. F. J. Urol. 1957, 77, 697.